Journal of the American College of Cardiology Vol. 45, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.

Transcription

1 Journal of the American College of Cardiology Vol. 45, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.00 Published by Elsevier Inc. doi: /j.jacc Effects of Candesartan on Cardiac Sympathetic Nerve Activity in Patients With Congestive Heart Failure and Preserved Left Ventricular Ejection Fraction Shu Kasama, MD,* Takuji Toyama, MD,* Hisao Kumakura, MD, Yoshiaki Takayama, MD, Shuichi Ichikawa, MD, Tadashi Suzuki, MD,* Masahiko Kurabayashi, MD* Maebashi and Gunma, Japan Heart Failure OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS We sought to evaluate the effects of angiotensin receptor blocker (ARB) on cardiac sympathetic nerve activity (CSNA) in patients with congestive heart failure (CHF) with a preserved left ventricular ejection fraction (LVEF). Approximately 50% of patients with CHF have preserved LVEF. It is reported that ARB therapy improves CSNA in CHF patients and reduced LVEF. However, the effect of ARB therapy on CSNA evaluated by iodine-123 meta-iodobenzylguanidine ( 123 I-MIBG) scintigraphy has not been determined in CHF patients with preserved LVEF. We selected 50 patients with nonischemic CHF and LVEF 40% who were treated with standard therapy. Twenty-five patients were randomized to also receive candesartan, whereas the remaining 25 patients received placebo. The delayed heart/mediastinum count (H/M) ratio, delayed total defect score (TDS), and washout rate (WR) were determined by 123 I-MIBG scintigraphy before and six months after treatment. The LV end-diastolic volume and LVEF were determined by echocardiography, and the plasma brain natriuretic peptide (BNP) concentration was also measured. In patients receiving candesartan, 123 I-MIBG scintigraphic and echocardiographic parameters were significantly improved after treatment. In contrast, there were no significant changes in these parameters in patients receiving placebo. There was a significant correlation between the changes in 123 I-MIBG scintigraphic findings and the percent change in BNP from baseline to six months in patients receiving candesartan (TDS: r 0.587, p 0.005; H/M ratio: r 0.509, p 0.01; WR: r 0.602, p 0.005). Adding candesartan to standard therapy can improve CSNA and LV performance in CHF patients with preserved LVEF. (J Am Coll Cardiol 2005;45:661 7) 2005 by the American College of Cardiology Foundation Approximately one-half of the patients with congestive heart failure (CHF) do not have a reduced left ventricular ejection fraction (LVEF) (1). Although patients with an LVEF 40% have a poor prognosis, even those with an LVEF 40% (preserved LVEF) have high rates of death and hospital admission due to CHF (1). In the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved study (2), part of the CHARM program (3), Yusuf et al. showed that the angiotensin receptor blocker (ARB) candesartan could reduce the number of hospital admissions for CHF in patients with heart failure and an LVEF 40%. Cardiac imaging with iodine-123 meta-iodobenzylguanidine ( 123 I-MIBG), an analogue of norepinephrine, is a useful tool for detecting abnormalities of the myocardial adrenergic nervous system in patients with CHF (4 6). Furthermore, cardiac sympathetic nerve activity evaluated by 123 I-MIBG scintigraphy has useful prognostic value in From the *Department of Cardiovascular Medicine, Gunma University School of Medicine, Maebashi, Japan; and Cardiovascular Hospital of Central Japan, Gunma, Japan. Manuscript received July 21, 2004; revised manuscript received October 13, 2004, accepted November 11, patients with CHF (6). Several studies have suggested that treatment of heart failure in patients with CHF can improve cardiac sympathetic nerve activity, as demonstrated by cardiac 123 I-MIBG scintigraphy (7 14). In these studies, all of the patients evaluated by 123 I-MIBG had impaired LV function, and there have been no reports on the use of cardiac 123 I-MIBG scintigraphy to evaluate the effect of adding candesartan to standard therapy in CHF patients with preserved LVEF. Accordingly, this study was performed to determine whether candesartan could improve cardiac sympathetic nerve activity in patients with CHF and an LVEF 40%. METHODS Patients. From January 2002 to September 2003, 50 patients were admitted to our institution with their first episode of nonischemic heart failure and preserved LVEF. We confirmed that all patients had symptoms and signs of congestive heart failure in this study. A detailed history was taken, and physical examination was performed before inclusion in the study. Chest radiography, standard electrocardiography, echocardiography, cardiac catheterization (including coronary angiography and left ventriculography),

2 662 Kasama et al. JACC Vol. 45, No. 5, 2005 Candesartan and Sympathetic Nerve Activity March 1, 2005:661 7 Abbreviations and Acronyms ARB angiotensin receptor blocker BNP brain natriuretic peptide CHF congestive heart failure H/M heart/mediastinum count LVEDV left ventricular end-diastolic volume LVEF left ventricular ejection fraction 123 I-MIBG iodine-123 meta-iodobenzylguanidine NYHA New York Heart Association TDS total defect score WR washout rate and thallium-201 and 123 I-MIBG scintigraphy were also performed for all patients. The subjects included 33 men and 17 women (mean age 66.3 years [range 48 to 85 years]). They were in New York Heart Association (NYHA) functional class II or III at the time of enrollment, and all had an LVEF 40%. The cause of CHF was hypertensive heart disease (n 31), valvular heart disease (n 10), or idiopathic cardiomyopathy (n 9). Patients were excluded if they had a history of myocardial infarction, coronary artery disease, congenital heart disease, primary hepatic failure, or active cancer. Cardiac medications at baseline and follow-up included an angiotensin-converting enzyme (ACE) inhibitor in 47 patients and a loop diuretic in 45 patients, as well as a beta-blocker in 6 patients and spironolactone in 9 patients (Table 1). The management of the patients was decided by the attending physician. The study was approved by the Table 1. Baseline Characteristics of the Subjects Candesartan (n 25) Placebo (n 25) p Value Age (yrs) NS Gender (male/female) 17/8 16/9 NS NYHA functional class II/III 16/9 17/8 NS Cause of CHF Hypertensive NS Valvular 5 5 NS Idiopathic 4 5 NS 123 I-MIBG TDS NS H/M ratio NS WR NS Echocardiography LVEDV (ml) NS LVEF(%) NS Plasma BNP (pg/ml) Medical treatment NS ACE inhibitor Loop diuretic Beta-blocker 3 3 Spironolactone 4 5 Data are presented as the mean value SD. ACE angiotensin-converting enzyme; BNP brain natriuretic peptide; CHF congestive heart failure; H/M heart/mediastinum count; LVEDV left ventricular end-diastolic volume; LVEF left ventricular ejection fraction; MIBG meta-iodobenzyleguanidine; NYHA New York Heart Association; TDS total defect score; WR washout rate. ethics review board of our institution, and written, informed consent was obtained from all patients. Study protocol. The subjects were randomly classified into two groups in a double-blinded manner (i.e., 25 patients receiving candesartan in addition to baseline therapy and 25 receiving placebo). The initial daily dose of candesartan was 2 to 4 mg, which was increased to a maintenance dose of 8 to 12 mg/day (mean 10 2 mg/day). Examinations were conducted before and after six months of treatment. Cardiac 123 I-MIBG scintigraphy. The method of 123 I- MIBG imaging has been described previously (10 14). The tracer was obtained from Daiichi Radioisotope Laboratories (Tokyo, Japan), and a dose of 111 MBq was injected intravenously while the patient was in a supine position. Anterior planar images and single-photon emission computed tomography (SPECT) images were acquired at 15 min after injection and again 4 h later. SPECT imaging was performed using a single-head gamma camera (Millennium MPR, GE Medical Systems, Waukesha, Wisconsin). The validation parameters of the gamma camera were within the specified limits. Images were acquired for 40 s in each of the 32 steps over a 180 orbit and recorded digitally at a resolution of pixels from the anterior planar 123 I-MIBG image. The heart/mediastinum count (H/M) ratio was determined from the delayed anterior planar 123 I-MIBG image. The washout rate (WR) was calculated using the following formula: ([(H)-(M)]early [(H)-(M)delayed)/[(H)- (M)]early 100 (%), where (H) mean count per pixel in the left ventricle, and (M) mean count per pixel in the upper mediastinum. The delayed myocardial SPECT images of each patient were divided into 20 segments (i.e., short-axis images obtained at the basal, middle, and apical levels of the ventricle were divided into six segments each, and the apical part of the vertical long-axis image was divided into two segments). Regional tracer uptake was then assessed semiquantitatively using a 4-point scoring system (0 normal uptake; 1 mildly reduced uptake; 2 moderately reduced uptake; 3 severely reduced uptake). In addition, the total defect score (TDS) was calculated as the sum of all defect scores. Assessment was performed in a blinded fashion by two independent observers with no knowledge of the clinical status or medical therapy of the patients. The level of interobserver agreement was highly significant (r 0.90, p 0.001). At our laboratory, the normal range for the delayed TDS is 6 to 10; the delayed H/M ratio is 2.00 to 2.80; and the normal WR range is 22% to 32%. We confirmed that the delayed TDS of normal subjects correlated with the normal WR (r 0.766, p 0.001). There was also a significant correlation between the normal delayed H/M ratio and normal WR (r 0.718, p 0.001). Echocardiography. Echocardiography was performed using standard methods in a blinded manner before and after six months of treatment. Two independent, experienced

3 JACC Vol. 45, No. 5, 2005 March 1, 2005:661 7 Kasama et al. Candesartan and Sympathetic Nerve Activity 663 Table 2. Changes in Total Defect Score, Heart/Mediastinum Count Ratio, and Washout Rate of Patients in Candesartan and Placebo Groups Candesartan Placebo Baseline 6 Months Baseline 6 Months 123 I-MIBG TDS * H/M ratio WR *p vs. baseline. p vs. baseline. p 0.05 vs. placebo at 6 months. p vs. placebo at 6 months. Data are presented as the mean value SD. H/M heart/mediastinum count; MIBG meta-iodobenzylguanidine; TDS total defect score; WR washout rate. echocardiographers who had no knowledge of the study performed all of the measurements. Left ventricular enddiastolic volume (LVEDV) and LVEF were calculated using the modified method of Simpson (15). Measurement of BNP. Blood samples were collected into test tubes containing EDTA after the patient had rested in a supine position for at least 30 min. Plasma was separated by centrifugation and frozen at 84 C. The plasma concentration of brain natriuretic peptide (BNP) was then measured with a specific immunoradiometric assay for human BNP using a commercial kit (Shionogi, Osaka, Japan). The percent change in the BNP level from baseline to six months was calculated using the following formula: ([BNP after 6 months] [BNP before treatment]/[bnp before treatment]) 100 (%). Statistical analysis. Statistical analysis was performed using StatView software (Abacus Concepts, Berkeley, California) for Macintosh (Apple Computer, Inc., Cupertino, California). The numerical results are expressed as the mean value SD. Comparison of baseline categorical data between the two groups was conducted using the chi-square test, and differences between continuous variables were evaluated using the unpaired t test. Changes in NYHA functional class were assessed using the Wilcoxon matched pairs signed rank test. In patients who underwent repeat assessment, changes from baseline were evaluated within each treatment group using a paired t test and between the candesartan and placebo groups using two-way analysis of variance. Linear regression analysis was used to determine the relationship between continuous variables. In all analyses, p 0.05 was considered statistically significant. RESULTS Clinical characteristics. There were no significant differences in hemodynamic characteristics or cardiac medications between the two groups on entry into the study. Before treatment, the TDS, H/M ratio, WR, LVEDV, LVEF, NYHA functional class, and plasma BNP concentration were similar in both groups (Table 1). None of the patients changed their baseline cardiac medication during the follow-up period. The mean dose of enalapril was mg/day in the candesartan group versus mg/day in the placebo group (p NS). The mean dose of perindopril was mg/day in the candesartan group versus mg/day in the placebo group (p NS). The mean dose of carvedilol was 13 6 mg/day in the candesartan group versus 13 6 mg/day in the placebo group (p NS). The mean dose of furosemide was mg/day in the candesartan group versus mg/day in the placebo group (p NS). Furthermore, the dose of spironolactone was only 25 mg/day in both groups. All patients were clinically stable, and no major events occurred during the follow-up period. Comparison of changes in hemodynamics before and after treatment. After six months, systolic and diastolic blood pressure tended to decrease in patients receiving candesartan ( vs mm Hg, and vs mm Hg, respectively). However, there were no significant differences in these parameters. In patients receiving placebo, there were no significant differences between baseline systolic and diastolic blood pressure and after six months ( vs mm Hg and vs mm Hg, respectively). In both groups, the heart rate did not change significantly after six months (in patients receiving candesartan, from beats/min to beats/min; in patients receiving placebo, from beats/min to beats/min). Comparison of cardiac 123 I-MIBG scintigraphic findings before and after treatment. The TDS, H/M ratio, and WR data are shown in Table 2. In the patients receiving candesartan, the TDS decreased significantly after six months (23 8) compared with the baseline value (28 8, p ). In the patients receiving placebo, however, there was no significant difference between the baseline TDS and that after six months. Furthermore, the TDS of patients receiving candesartan was significantly lower than that of patients receiving placebo after six months (p 0.05). Segmental analysis of the defect scores in both groups showed improvement in uptake by the inferior wall, although the change was not statistically significant. In the patients receiving candesartan, the H/M ratio increased significantly after six months ( ) compared with the baseline value ( , p 0.005). In the patients receiving placebo, however, there was no significant difference between the value at baseline and that after six months. Furthermore, the H/M ratio of patients receiving candesar-

4 664 Kasama et al. JACC Vol. 45, No. 5, 2005 Candesartan and Sympathetic Nerve Activity March 1, 2005:661 7 Figure 1. Representative anterior planar delayed 123 I-meta-iodobenzylguandine images before and after treatment from the candesartan group. In this example, the delayed heart/mediastinum count ratios before and after treatment were 1.89 and 2.21, respectively. The washout rates before and after treatment were 45% and 27%, respectively. tan was significantly higher than that of patients receiving the placebo after six months (p 0.005). Candesartan treatment caused the WR to decrease significantly after six months (32 8%) compared with the baseline values (37 11%, p 0.005). In contrast, there were no significant differences between the values at baseline and six months in the patients treated with placebo. Furthermore, the WR of patients receiving candesartan was significantly lower than that of patients receiving the placebo after six months (p 0.005). Representative 123 I-MIBG images for both groups before and after treatment are shown in Figures 1 and 2. Comparison of echocardiographic findings before and after treatment. The LVEDV and LVEF data are shown in Table 3. In the patients receiving candesartan, the LVEDV decreased significantly after six months (90 27 ml) compared with the baseline value ( ml, p 0.05). In the patients receiving placebo, however, there were no significant differences between the LVEDV at baseline and that after six months. The LVEF increased significantly after six months of candesartan therapy (58 10%) relative to the baseline value (54 7%, p 0.05). In contrast, there was no significant difference between the LVEF at baseline and that after six months in the patients receiving placebo. Comparison of NYHA functional class before and after treatment. The NYHA functional class status of the patients is shown in Table 3 and Figure 3. Patients from both groups showed improvement after six months of treatment Figure 2. Representative anterior planar delayed 123 I-meta-iodobenzylguandine images before and after treatment from the placebo group. In this example, the delayed heart/mediastinum count ratios before and after treatment were 1.93 and 1.81, respectively. The washout rates before and after treatment were 42% and 46%, respectively. relative to the baseline status (patients receiving candesartan, p 0.001; patients receiving placebo, p 0.05). After six months, the NYHA functional class status of patients receiving candesartan was better than that of patients receiving placebo (p 0.05). Comparison of BNP before and after treatment. Plasma BNP concentrations are shown in Table 3. In patients receiving candesartan, the plasma BNP concentration decreased significantly after six months ( pg/ml) compared with the baseline value ( pg/ml, p 0.001). In contrast, there was no significant difference between the BNP values at baseline and after six months in the patients receiving placebo. Relationship between percent change in BNP and 123 I- MIBG scintigraphic findings before and after treatment. There was a significant correlation between the changes in 123 I-MIBG scintigraphic findings and the percent change in BNP from baseline to six months (Fig. 4) in the patients receiving candesartan (TDS: r 0.587, p 0.005; H/M ratio: r 0.509, p 0.01; and WR: r 0.602, p 0.005). In contrast, there was no relationship between BNP and scintigraphic parameters in the patients receiving placebo. DISCUSSION Our findings demonstrate for the first time that the addition of candesartan to standard therapy could improve cardiac sympathetic nerve activity and cardiac function in CHF patients with preserved LVEF. The potential adverse effects of angiotensin on cardiovascular function make its inhibition an attractive therapeutic approach to heart failure. Although ACE inhibitors were designed to decrease the circulating and tissue concentrations of angiotensin II (A-II), recent evidence suggests that the current therapeutic regimens using ACE inhibitors do not adequately suppress A-II production (16). Several reports have suggested an important role of non ACEmediated enzymatic pathways in the conversion of angiotensin I to A-II (17,18). Therefore, the strategy of providing more comprehensive blockade of angiotensin with the ARB candesartan appears to be a rational treatment for heart failure. It has been reported that there are several subtypes of the A-II receptor (19), among which the AT 2 receptor is known to have an antagonistic action on the AT 1 receptor and thus has a beneficial effect on the myocardium (19). Therefore, because the ARB candesartan selectively inhibits the AT 1 receptor, this drug may have a superior cardioprotective effect compared with ACE inhibitor treatment alone. Cohn et al. (20) reported that the addition of an ARB could significantly improve cardiac function and reduce both mortality and morbidity in patients with heart failure. In the present study, LV volume and cardiac function both significantly improved by adding candesartan to the standard therapy. When we evaluated other echocardiographic data,

5 JACC Vol. 45, No. 5, 2005 March 1, 2005:661 7 Kasama et al. Candesartan and Sympathetic Nerve Activity 665 Table 3. Changes in Left Ventricular End-Diastolic Volume, Left Ventricular Ejection Fraction, Functional Class, and Plasma Brain Natriuretic Peptide Level of Patients in the Candesartan and Placebo Groups Candesartan Placebo Baseline 6 Months Baseline 6 Months LVEDV (ml) * LVEF (%) * NYHA functional class I/II/III 0/16/9 12/13/0 0/17/8 11/8/6* Plasma BNP (pg/ml) *p 0.05 vs. baseline. p vs. baseline. p 0.05 vs. placebo at 6 months. Data are presented as the mean value SD. BNP brain natriuretic peptide; LVEDV left ventricular end-diastolic volume; LVEF left ventricular ejection fraction; NYHA New York Heart Association. including mitral regurgitation and diastolic parameters (the E/A ratio and deceleration time), a marked improvement was observed in both groups, but there were no significant intergroup differences in the changes (data not shown). Moreover, the addition of candesartan also improved the symptoms of heart failure, as shown by changes in NYHA functional class. Iodine-123 MIBG is an analogue of the adrenergic neuron-blocking agent guanethidine, which is thought to utilize the same myocardial uptake and release mechanisms as norepinephrine (21). The myocardial norepinephrine concentration and 123 I-MIBG uptake correlate in patients with CHF (5), so cardiac 123 I-MIBG imaging seems to be a useful tool for detecting abnormalities of the myocardial adrenergic nervous system in CHF patients (4 6). Furthermore, cardiac sympathetic nerve activity evaluated by 123 I- MIBG scintigraphic findings and LV function correlate (6), and 123 I-MIBG scintigraphy has useful prognostic value for patients with CHF (6). In patients with nonischemic cardiomyopathy, a large proportion of the reduced uptake of norepinephrine is probably due to a loss of neuronal norepinephrine from the failing myocardium. However, some of the reduction appears to be functional (i.e., reversible) and is mediated by hormonal factors, including angiotensin and aldosterone. Struthers (22) reported that once norepinephrine is taken up by cardiac myocytes, it is rapidly metabolized and inactivated, so that such uptake is equivalent to local removed by the myocardium. Several reports have suggested that ACE inhibitors (7,8), beta-blockers (8 10), spironolactone (11,12), and ARBs (13) can improve cardiac sympathetic nerve activity in patients with CHF, based on cardiac 123 I-MIBG scintigraphic findings. However, all of the CHF patients in these studies had poor LV function, and there have been no reports on the use of cardiac 123 I-MIBG scintigraphy to evaluate the effect of heart failure therapy in CHF patients with preserved LVEF. Before treatment of the patients in this study, the TDS and WR were relatively lower and the H/M ratio was relatively higher than in our previous reports (10 13). Thus, these findings provide the first evidence indicating that cardiac sympathetic nerve activity is impaired less severely in CHF patients with preserved LVEF than in patients with poor LV function. In addition, these findings are consistent with the observation that the changes in 123 I-MIBG scintigraphic parameters after candesartan treatment are less remarkable compared with those in patients with reduced LV function. In general, the decreased TDS and H/M ratio in the failing myocardium are related to impaired neuronal uptake, whereas increased WR reflects enhanced neurotransmitter Figure 3. Changes in the New York Heart Association (NYHA) functional class during treatment in the two groups.

6 666 Kasama et al. JACC Vol. 45, No. 5, 2005 Candesartan and Sympathetic Nerve Activity March 1, 2005:661 7 Figure 4. Correlation between changes in the 123 I-meta-iodobenzylguandine scintigraphic findings and the percent change in brain natriuretic peptide (BNP) from baseline to six months in patients receiving candesartan. Delta TDS total defect score value after six months pretreatment TDS value; delta H/M ratio heart/mediastinum count ratio after six months pretreatment H/M ratio; delta WR washout rate after six months pretreatment WR. release by the adrenergic nerves of the myocardium. Therefore, the TDS and H/M ratio are decreased and WR increased in patients with a failing myocardium, and the use of therapeutic agents improves these parameters (7 14). In this study, these parameters improved after the addition of candesartan to the standard therapy. There are several possible reasons for this beneficial effect. First, the addition of candesartan to an ACE inhibitor may result in stronger inhibition of the renin-angiotensin-aldosterone system, which ameliorates cardiac function. Second, candesartan by itself may exert favorable effects on cardiac function irrespective of concomitant use of an ACE inhibitor. Third, candesartan may play a cardioprotective role by increasing the myocardial uptake of norepinephrine and reducing norepinephrine release, given that the ARB inhibits betaadrenergic receptor-mediated signaling as well as A-II receptor, as reported by Rockman et al. (23,24). The plasma BNP level is a useful prognostic indicator in patients with CHF (25), because it is a ventricular hormone (26). Treatment of CHF guided by the plasma BNP level has been reported to reduce cardiovascular events (27), so a decrease in BNP may be associated with a better outcome, as is the case in the CHARM-Preserved study (2). Moreover, Latini et al. (28) reported that plasma BNP concentration is the most powerful indicator after ARB therapy in patients with CHF. In our study, plasma BNP concentrations significantly decreased due to the addition of candesartan to standard therapy in CHF patients with preserved LVEF. Furthermore, we detected a significant correlation between changes in the 123 I-MIBG scintigraphic findings and the percent change in BNP from baseline to six months of candesartan treatment in CHF patients with preserved LVEF. In our study, almost all of the patients were treated with ACE inhibitors at baseline. The echocardiographic and 123 I-MIBG scintigraphic parameters and plasma BNP level tended to improve in patients receiving the placebo, but the changes were not statistically significant. Therefore, it may be important to further inhibit the renin-angiotensinaldosterone system by adding candesartan to ACE inhibitors in CHF patients with preserved LVEF. Study limitations. The small number of patients included in this study was a major limitation. In addition, the dose of candesartan was relatively low. In the future, we need to study the long-term effects of candesartan on cardiac sympathetic nerve activity in a larger group of patients. Recently, it has been reported that aldosterone is produced in the ventricles of patients with heart failure (29), and that the aldosterone synthase gene is expressed in cardiac tissue (30). Furthermore, it has been reported that aldosterone could induce the expression of ACE messenger ribonucleic acid in cultured neonatal cardiocytes (31). We did not measure plasma renin activity or the aldosterone concentration. However, the local renin-angiotensinaldosterone system may be activated even if the plasma renin activity or aldosterone concentration is normal. Therefore, adding candesartan to standard therapy may be important to more completely inhibit the renin-angiotensin-aldosterone system in CHF patients with preserved LVEF. In this study, hypertensive heart disease was a major cause of heart failure in both groups. In general, patients with high blood pressure had impaired cardiac sympathetic nerve activity, and the use of agents improved 123 I-MIBG scintigraphy (32). In patients receiving candesartan in our study, there were no significant differences in blood pressure after six months. Therefore, we believe that adding candesartan to standard therapy can improve cardiac sympathetic nerve activity in CHF patients with preserved LVEF even if blood pressure is not affected. Conclusions. The TDS, H/M, and WR determined by 123 I-MIBG scintigraphy were all significantly improved after six months of candesartan treatment. The LV volume and cardiac function were also improved due to candesartan therapy. Furthermore, the plasma BNP concentration was decreased significantly. There was a significant correlation between changes in the 123 I-MIBG scintigraphic findings and the percent change in BNP from baseline to six months in patients receiving candesartan. These findings suggest that adding candesartan to standard therapy can improve cardiac sympathetic nerve activity and LV performance in CHF patients with preserved LVEF.

7 JACC Vol. 45, No. 5, 2005 March 1, 2005:661 7 Kasama et al. Candesartan and Sympathetic Nerve Activity 667 Reprint requests and correspondence: Dr. Shu Kasama, Department of Cardiovascular Medicine, Gunma University School of Medicine, , Showa-machi, Maebashi, Gunma , Japan. s-kasama@bay.wind.ne.jp. REFERENCES 1. Redfield MM, Jacobsen SJ, Burnett JC Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289: Yusuf S, Pfeffer MA, Swedberg K, et al., the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM- Preserved trial. Lancet 2003;362: McMurray J, Ostergren J, Pfeffer M, et al., the CHARM Committees and Investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure- Assessment of Reduction in Mortality and morbidity (CHARM) program. Eur J Heart Fail 2003;5: Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78: Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine- 123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12: Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac meta-iodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33: Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-mibg release in heart failure. J Nucl Med 1997;38: Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40: Toyama T, Hoshizaki H, Seki R, et al. Efficacy of carvedilol treatment on cardiac function and cardiac sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with metoprolol therapy. J Nucl Med 2003;44: Kasama S, Toyama T, Hoshizaki H, et al. Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympathetic nerve activity, cardiac function, and symptoms after treatment in patients with dilated cardiomyopathy. Chest 2002;122: Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43: Kasama S, Toyama T, Kumakura H, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003;41: Kasama S, Toyama T, Kumakura H, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44: Kasama S, Toyama T, Kumakura H, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med 2004;45: Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2: Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN, the Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99: Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res 1990;66: Balcells E, Meng QC, Johnson WH Jr., et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;273:H Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors: a report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 1991;17: Cohn JN, Tognoni G, the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345: Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [ 131 I]iodobenzylguanidine. J Nucl Med 1980; 21: Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2: Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 2003;108: Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembranespanning receptors and heart function. Nature 2002;415: Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96: Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90: Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355: Latini R, Masson S, Anand I, et al., for the Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25: Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103: Yoshimura M, Nakamura S, Ito T, et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002;87: Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001;104: Sakata K, Shirotani M, Yoshida H, Kurata C. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 1998;32: